Gamma-globin gene regulatory machinery

The gamma-globin gene regulatory machinery is a complex system of proteins and DNA elements that orchestrate the expression of the HBG1 and HBG2 genes, which encode the gamma-globin subunits of fetal hemoglobin (HbF) (Sankaran et al., 2008). In healthy adults, this machinery silences gamma-globin expression through a process known as hemoglobin switching, primarily mediated by repressors like BCL11A and ZBTB7A (LRF) (Masuda et al., 2016). This regulatory network is a major therapeutic target for beta-hemoglobinopathies, such as sickle cell disease and beta-thalassemia, where the reactivation of HbF can compensate for defective adult beta-globin (Bauer et al., 2012). Pharmacological agents like hydroxyurea and decitabine have long been used to modulate this machinery, though their effects are often indirect or non-specific (Platt, 2008). Recent breakthroughs in gene editing, specifically exagamglogene autotemcel, target the erythroid-specific enhancer of BCL11A to disrupt this repressive machinery and restore HbF production (Frangoul et al., 2021). By precisely manipulating these regulatory elements, clinicians can achieve high levels of HbF, significantly reducing the clinical complications of hemoglobin disorders.

Other names

Fetal hemoglobin regulatory complexHBG1/HBG2 regulatory networkGamma-globin repressor complexHbF switching machinery

Induction of fetal hemoglobin (HbF) by inhibiting transcriptional repressors such as BCL11A and ZBTB7A, or by altering the epigenetic state of the HBG1/HBG2 gene promoters to facilitate transcription in adult erythroid cells (Sankaran et al., 2008; Masuda et al., 2016).